Abstract 450P
Background
Neuroendocrine neoplasms (NENs) are a rare group of malignancies with significant mortality. Recently, Grade 3 (G3) NENs have been dichotomised into well-differentiated neuroendocrine tumours (NETs) and poorly differentiated carcinomas (NECs), with seemingly different characteristics. Treatment for these groups differs, although there is not enough evidence to identify a uniform standard of care. We aim to understand whether the difference between NET and NEC G3 is clinically significant, and if so, what these are in terms of their clinical characteristics.
Methods
A retrospective cohort study was done to identify patients diagnosed with NEN G3 in Nottinghamshire. Patients were included if they were diagnosed after 2017 with Ki-67 score of >20%, which is metastatic and not amenable to curative treatment. Patients with neoplasms that exhibit large- or small-cell like morphology were excluded. Clinical characteristics and treatment were collected and analysed using Kaplan-Meier curves and ANOVA.
Results
22 patients were included. The mean overall survival (OS) of the cohort was 778 days and the median OS was 461 days. Median OS for patients with Ki-67 score ≥40% was 861 days, as compared to 217 days for patients with a score <40% (p=0.078). Median OS for patients with unknown primary site was worse, followed by pancreatic (217 days vs 461 days; p=0.939). Mean first-line progression free survival (PFS) for patients who did not receive platinum-based chemotherapy was numerically superior than for patients who did receive this (449 vs 127 days; p<0.001). Mean first-line PFS for patients who received alkylating-based chemotherapy was higher than for patients who did not receive this (228.22 vs 156.46 days; p=0.003). Capecitabine and temozolomide treatment had the best objective response rate at 54.5%.
Conclusions
This study described the histopathological and clinical factors of high-grade NENs. These findings contribute to a better understanding of the prognostic significance of factors in this group of neoplasms, sufficient to rationalise a difference in care for patients with G3 NETs and true high-grade NECs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06